Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Parexel launches medical writing solutions business

Will develop a variety of communication services

- PMLiVE

No one is listening to you!

We know it is harsh but you know how frustrating it is. You want them to embrace change but they’ve got cloth ears. That’s why we have produced a guide,...

Page & Page Health

The challenges of making genomics a reality for patients

Collaboration is key

How can pharma engage with key decision-makers in new, collaborative NHS care models?

Paul Midgley, Sue Thomas, Steve How and Oli Hudson, of Wilmington Healthcare, explore how pharma should adapt its approach

Wilmington Healthcare

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

- PMLiVE

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Offers €15m upfront for the anti-SIRP-alpha antibody and €15m when it reaches phase I testing

The two ‘c’s’ of public health: confounding and causal inference*

Rerum cognoscere causas. This phrase translates as ‘to know the causes of things’. It is the basis and impetus of public health. But epidemiologists have a different word for it:...

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

Segmentation, evolved

My research into the evolution of the life science industry reveals broad, sweeping trends, as I wrote about in previous PME articles such as “Selection Pressures” and “Explosive Evolution”. But...

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links